BIOARCTIC Aktie

>BIOARCTIC Aktienkurs

30.2 EUR -2.0% (TradegateBSX)

Ask: 30.5 EUR / 40 Stück

Bid: 30.22 EUR / 40 Stück

Tagesumsatz: 24 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

BIOARCTIC Aktie über LYNX handeln

Intraday

1 Jahr

>BIOARCTIC Performance

1 Woche: +3,2%

1 Monat: +10,3%

3 Monate: +4,1%

6 Monate: +6,1%

1 Jahr: +86,4%

laufendes Jahr: +4,4%

>BIOARCTIC Aktie

Name:

BIOARCTIC AB B

Land:

Schweden

Sektor:

Gesundheit

ISIN/ Wkn:

SE0010323311 / A2H5GS

Symbol/ Ticker:

B9A (Frankfurt)

Kürzel:

FRA:B9A, ETR:B9A, B9A:GR

Index:

Webseite:

https://www.bioarctic.se/

Profil:

BioArctic AB (publ) is a Swedish research-based biopharmaceutical company specializing in disease-modifying treatments for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS. Founded in 2003 by Professor Lars Lannfelt and Dr. P�..
>Volltext..

Marktkapitalisierung:

2724.11 Mio. EUR

Unternehmenswert:

2526.47 Mio. EUR

Umsatz:

187.39 Mio. EUR

EBITDA:

Nettogewinn:

95.83 Mio. EUR

Gewinn je Aktie:

1.08 EUR

Schulden:

4.13 Mio. EUR

Liquide Mittel:

97.52 Mio. EUR

Operativer Cashflow:

134.14 Mio. EUR

Bargeldquote:

4.21

Umsatzwachstum:

723.13%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Div. Historie:

10.05.19 - 0.13599€

Insiderhandel:

Suchwörter:

BIOARCTIC

Letzte Datenerhebung:

05.04.26

>BIOARCTIC Kennzahlen

Aktien/ Unternehmen:

Aktien: 74.32 Mio. St.

Frei handelbar: 53.89%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: 131

Umsatz/Mitarb.: 1.43 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: -4.42%

Bewertung:

KGV: 28.61

KGV lG: 230.15

KUV: 11.79

KBV: 14.9

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 97.36%

Gewinnmarge: 51.14%

Operative Marge: 68.44%

Managementeffizenz:

Gesamtkaprendite: 55.46%

Eigenkaprendite: 71.44%

>BIOARCTIC Peer Group

Gesundheit, Neurologische- & psychische Behandlung/ Medizin, Antikörper- Behandlung

>BIOARCTIC Chart & Kurs - Tradegate

>BIOARCTIC News

27.03.26 - 10:24	The Nomination Committee′s proposal for the election of Board members and Chairperson of the Board in BioArctic AB (PR Newswire)
	STOCKHOLM, March 27, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Nomination Committee for BioArctic AB (publ) presents the following proposals regarding the resolution on the number of board members and the election of board members and......

23.03.26 - 08:57	New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress (PR Newswire)
	STOCKHOLM, March 23, 2026 /PRNewswire/ -- BioArctic's AB (publ) (STOCKHOLM: BIOA B ) partner Eisai presented new data at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™), held in Copenhagen, Denmark March 17-21.......

23.03.26 - 08:54	New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress (PR Newswire)
	STOCKHOLM, March 23, 2026 /PRNewswire/ -- BioArctic's AB (publ) (NASDAQ: BIOA B) partner Eisai presented new data at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™), held in Copenhagen, Denmark March 17-21. BioArctic......

11.03.26 - 08:33	Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress (PR Newswire)
	STOCKHOLM, March 11, 2026 /PRNewswire/ -- BioArctic's AB (publ) (STOCKHOLM: BIOA B) partner Eisai announced today that they will present the latest findings on lecanemab at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™......

11.03.26 - 08:27	Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress (PR Newswire)
	STOCKHOLM, March 11, 2026 /PRNewswire/ -- BioArctic's AB (publ) (STOCKHOLM: BIOA B) partner Eisai announced today that they will present the latest findings on lecanemab at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™......

27.02.26 - 19:03	Number of shares and votes in BioArctic AB (publ) as of February 27, 2026 (PR Newswire)
	STOCKHOLM, Feb. 27, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 78,000 Class B shares during February for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May......

20.02.26 - 10:31	Biogen und BioArctic: Debatte um Alzheimer-Mittel in Deutschland spitzt sich zu (Der Aktionaer)
	Im vergangenen Jahr hat Biogen mit seinem japanischen Partner Eisai das Alzheimer-Medikament Leqembi (Lecanemab) auch in Deutschland auf den Markt gebracht. Doch es herrschen Zweifel an der Wirksamkeit des Medikaments, welches seinen Ursprung bei der schwedischen BioArctic hat....

19.02.26 - 08:54	AKTIONÄR-Hot-Stock BioArctic schießt hoch: Dividenden-Überraschung! (Der Aktionaer)
	BioArctic, der ursprüngliche Entwickler des Alzheimer-Medikaments Leqembi (Lecanemab), hat am Mittwoch starke Zahlen zum vierten Quartal respektive Gesamtjahr vorgelegt. Darüber hinaus sorgt die Firma mit der Ankündigung einer Dividende für Aufsehen, was eher ungewöhnlich für eine Biotech-Gesellschaft ist....

18.02.26 - 23:48	BioArctic Interim Report for the period October - December 2025 (ShareCast)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

18.02.26 - 10:24	BioArctic Interim Report for the period October - December 2025 (ShareCast)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

18.02.26 - 10:06	BioArctic shares jump 10% as Leqembi royalties drive profit surge (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

18.02.26 - 08:54	BioArctic Interim Report for the period October - December 2025 (PR Newswire)
	STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- A transformative year with record financial results Events during the fourth quarter 2025 Leqembi® Iqlik™ was launched for weekly maintenance dosing and Eisai completed rolling sBLA submission for subcutaneous initiation treatment in the US Leqembi......

18.02.26 - 08:39	BioArctic Interim Report for the period October - December 2025 (PR Newswire)
	STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- A transformative year with record financial results Events during the fourth quarter 2025 Leqembi® Iqlik™ was launched for weekly maintenance dosing and Eisai completed rolling sBLA submission for subcutaneous initiation treatment in the US Leqembi......

11.02.26 - 08:45	Invitation to presentation of BioArctic′s fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET (PR Newswire)
	STOCKHOLM, Feb. 11, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's fourth quarter report for October - December 2025 on Wednesday, February 18, 2026, at 08:00 a.m. CET. In conjunction with the report, BioArctic invites investors, analysts,......

11.02.26 - 08:30

Invitation to presentation of BioArctic′s fourth quarter report for October – December 2025 on February 18 at 9.30 a.m. CET (Cision)

Stockholm, Sweden, February 11, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's fourth quarter report for October – December 2025 on Wednesday, February 18, 2026, at 08:00 a.m. CET. In conjunction with the report, BioArctic invites investors, analysts, and media to a presentation on February 18, at 09:30 a.m. CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, together with colleagues, will present and comment on the fourth quarter report, followed by a Q&A session. If you wish to participate via webcast, please use the link below. You will be...

09.02.26 - 07:12	BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China (PR Newswire)
	STOCKHOLM, Feb. 9, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the treatment of early Alzheimer's disease with Leqembi (lecanemab), using a subcutaneous autoinjector (SC-AI),......

09.02.26 - 07:06	BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China (PR Newswire)
	STOCKHOLM, Feb. 9, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the treatment of early Alzheimer's disease with Leqembi (lecanemab), using a subcutaneous autoinjector (SC-AI),......

06.02.26 - 12:27	Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025 (PR Newswire)
	STOCKHOLM, Feb. 6, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the fourth quarter 2025, in conjunction with their partner Biogen's fourth quarter report. In total, sales of JPY 20.7......

06.02.26 - 12:21	Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025 (PR Newswire)
	STOCKHOLM, Feb. 6, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the fourth quarter 2025, in conjunction with their partner Biogen's fourth quarter report. In total, sales of JPY 20.7......

26.01.26 - 22:15	Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab) (PR Newswire)
	STOCKHOLM, Sweden, Jan. 26, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing Authorisation Variation to the European Medicines Agency (EMA) for a once every four weeks intravenous (IV)......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram